Blood Screening definition

Blood Screening means the commercial use of products that detect nucleic acid sequences(s) for: (a) the screening of blood, plasma or blood components intended for transfusion; and (b) confirmatory or supplemental testing of the same samples otherwise screened for purposes described in Section 1.4(a).
Sample 1Sample 2Sample 3
Blood Screening means (i) the screening of blood, plasma or blood components intended for transfusion or for use in blood products (e.g., immunoglobulins), and (ii) the screening of any biological materials intended for transfusion or transplantation, in each case from any donor, including autologous donors.
Sample 1Sample 2Sample 3
Blood Screening means: (i) the screening of blood, plasma or blood components intended for transfusion or for use in blood products (e.g., immunoglobulins), and (ii) the screening of any biological materials intended for transfusion or transplantation, in each case from any donor, including autologous donors.
Sample 1

Examples of Blood Screening in a sentence

  • The parties shall develop reasonable procedures for requesting and delivering copies of such records to each other as may be necessary for the performance of the Development Programs for Blood Screening Assays and Blood Screening Instruments.

  • The parties entered into the Agreement as of June 11, 1998 pursuant to which, among other things, the parties described their respective rights and obligations with respect to the development, manufacture, marketing and distribution of Products in the Blood Screening and Clinical Diagnostic Fields.

  • Chiron shall use its Commercially Reasonable Efforts to promote, market, sell and meet the reasonably foreseeable market demands for the Initial Blood Screening Assays in the Territory to be conducted by the Blood Screening Instruments for use in the Blood Screening Field.

  • If the Applicable Purchase Price for a Future Blood Screening Assay sold by Chiron, its Affiliates, or the Major Distributor during such calendar month is less than the Transfer Price for such Future Blood Screening Assay previously paid by Chiron or its Affiliates to Gen-Probe, then Gen-Probe shall pay the difference to Chiron.

  • Within thirty (30) days after receipt of each shipment and invoice of Initial Blood Screening Assays from Gen-Probe, Chiron shall pay to Gen-Probe the Transfer Price for each Initial Blood Screening Assay purchased by Chiron or its Affiliates.

  • The Development Program as proposed by Gen-Probe for each Initial Blood Screening Assay may not be modified except by the action of the Supervisory Board.

  • In the event it undertakes or is assigned by the Supervisory Board any responsibilities in connection with the Development Program for each such Blood Screening Instrument, Chiron shall pay all Development Costs of conducting its obligations under the Development Program for the Blood Screening Instruments.

  • Within sixty (60) days after the end of each calendar quarter, Chiron shall pay to Gen-Probe the Applicable Royalty, if any, for each Future Blood Screening Assay sold by Chiron or its Affiliates during such calendar quarter.

  • Gen-Probe and Chiron shall conduct their respective obligations under the Development Program for each Future Blood Screening Assay in compliance in all material respects with all requirements of applicable laws and regulations and all applicable good laboratory, clinical and manufacturing practices.

  • The Supervisory Board will discuss Third Party patent rights which may be necessary for (i) Blood Screening Assays or (ii) modifications to Blood Screening Assays or Blood Screening Instruments.

Related to Blood Screening

  • Health screening means the use of one or more diagnostic tools to test a person for the presence or precursors of a particular disease.

  • Screening means the evaluation process used to identify an individual's ability to perform activities of daily living and address health and safety concerns.

  • Investigational Medicinal Product means the study drug or control material as defined in the Protocol.

  • Clinical laboratory means a facility for the microbiological, serological, chemical, hematological, radiobioassay, cytological, immunohematological, pathological, or other examination of materials derived from the human body for the purpose of providing information for the diagnosis, prevention, or treatment of a disease or assessment of a medical condition.

  • Assay means a laboratory analysis of Crude Petroleum to include the following: A.P.I. Gravity, Reid vapor pressure, composition, pour point, water and sediment content, sulfur content, viscosity, distillation, hydrogen sulfide, flash/boiling point and other characteristics as may be required by Carrier.

  • Manufacturing means all activities related to the manufacture of a Compound, including planning, purchasing, manufacture, processing, compounding, storage, filling, packaging, waste disposal, labeling, leafleting, testing, quality assurance, sample retention, stability testing, release, dispatch and supply, as applicable.

  • Field means all fields of use.

  • Study means the investigation to be conducted in accordance with the Protocol.

  • Phase I Study means a study in humans which provides for the first introduction into humans of a product, conducted in healthy volunteers or patients to obtain information on product safety, tolerability, pharmacological activity or pharmacokinetics, as more fully defined in 21 C.F.R. § 312.21(a) (or the non-United States equivalent thereof).

  • Manufacturing Technology means any and all patents, patent applications, Know-How, and all intellectual property rights associated therewith, and including all tangible embodiments thereof, that are necessary or useful for the manufacture of adeno- associated viruses, adeno-associated virus vectors, research or commercial reagents related thereto, Licensed Products, or other products, including manufacturing processes, technical information relating to the methods of manufacture, protocols, standard operating procedures, batch records, assays, formulations, quality control data, specifications, scale up, any and all improvements, modifications, and changes thereto, and any and all activities associated with such manufacture. Any and all chemistry, manufacturing, and controls (CMC), drug master files (DMFs), or similar materials provided to regulatory authorities and the information contained therein are deemed Manufacturing Technology.

  • Biomarker means a parameter or characteristic in a patient or Patient Sample, the measurement of which is useful (a) for purposes of selecting appropriate therapies or patient populations or monitoring disease susceptibility, severity or state, or monitoring therapies for such patient and/or (b) for predicting the outcome of a particular treatment of such patient.

  • Investigational Product means the Study Drug identified above and the control material, as further detailed in the Protocol;

  • Phase I Clinical Study means, as to a particular Licensed Product, an initial clinical study in humans with the purpose of assessing the Licensed Product’s safety, tolerability, toxicity, pharmacokinetics or other pharmacological properties.

  • Biological agent shall mean any pathogenic (disease producing) micro-organism(s) and/or biologically produced toxin(s) (including genetically modified organisms and chemically synthesized toxins) which cause illness and/or death in humans, animals or plants.